Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Valneva SE Preference Shares EUR0.01

Sell:€0.11 Buy:€0.12 Change: €0.004 (3.51%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:€0.11
Buy:€0.12
Change: €0.004 (3.51%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:€0.11
Buy:€0.12
Change: €0.004 (3.51%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden.

Contact details

Address:
Campus Bio-Ouest, 6, Rue Alain Bombard
SAINT-HERBLAIN
44800
France
Telephone:
+33 (2) 28073710
Website:
https://valneva.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
n/a
ISIN:
FR0011472943
Market cap:
€237.30 million
Shares in issue:
91.99 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Frederic Grimaud
    Chairman of the Supervisory Board
  • Thomas Lingelbach
    Chairman of the Management Board, Member of the Executive Committee
  • Franck Grimaud
    Chief Executive Officer, Member of the Management Board, Member of the Executive Committee
  • James Sulat
    Independent Vice Chairman of the Supervisory Board
  • David Lawrence
    Chief Financial Officer, Member of the Management Board
  • Manfred Tiefenbacher
    Vice President - Finance, Member of the Executive Committee
  • Frederic Jacotot
    Vice President, General Counsel, Member of the Management Board, Member of the Executive Committee , General Secretary
  • Jason Golan
    Vice President Commercial Operations, Member of the Executive Committee
  • Olivier Jankowitsch
    Vice President Global Supply Operations, Member of the Executive Committee
  • Andreas Meinke
    Vice President Pre-clinical & Translational Research, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.